Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1

被引：0

作者：

Kilickap, S. ^{[1
]}

Sezer, A. ^{[2
]}

Ozguroglu, M. ^{[3
]}

Gumus, M. ^{[4
]}

Bondarenko, I. ^{[5
]}

Gogishvili, M. ^{[6
]}

Nechaeva, M. ^{[7
]}

Schenker, M. ^{[8
]}

Cicin, I. ^{[1
]}

Fuang, H. G. ^{[9
]}

Kulyaba, Y. ^{[10
]}

Zyuhal, K. ^{[11
]}

Scheusan, R. I. ^{[12
]}

Baramidze, A. ^{[13
]}

Garassino, M. C. ^{[14
]}

Li, Y. ^{[15
]}

Jia, X. ^{[15
]}

Kaul, M. ^{[15
]}

Perez, J. ^{[15
]}

Seebach, F. ^{[15
]}

Lowy, I. ^{[15
]}

Pouliot, J. F. ^{[15
]}

Kim, E. ^{[15
]}

Rietschel, P. ^{[15
]}

Magnan, H. ^{[15
]}

机构：

[1] Istinye Univ, Fac Med, Istanbul, Turkiye

[2] Baskent Univ, Adana, Turkiye

[3] Istanbul Univ Cerrahpasa, Istanbul, Turkiye

[4] Istanbul Medeniyet Univ, Istanbul, Turkiye

[5] Dnipropetrovsk Med Acad, Dnipro, Ukraine

[6] Univ Clin, High Technol Med Ctr, Tbilisi, Georgia

[7] Div Arkhangelsk Clin Oncol Ctr, Arkhangelsk, Russia

[8] Centrul Oncol Sf Nectarie SRL, Craiova, Romania

[9] Univ Malaya, Kuala Lumpur, Malaysia

[10] Prognosis Optima LLC, Kyiv, Ukraine

[11] Multiprofile Hosp Active Treatment, Dobrich, Bulgaria

[12] Oncocenter Oncol Clin, Timisoara, Romania

[13] Todua Clin, Tbilisi, Georgia

[14] Univ Chicago, Knapp Ctr Biomed Discovery, Chicago, IL USA

[15] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA11.06

引用

页码：S35 / S35

页数：1

共 50 条

[1] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
Gumus, Mahmut
Chen, Chieh-, I
Ivanescu, Cristina
Kilickap, Saadettin
Bondarenko, Igor
Ozguroglu, Mustafa
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Harnett, James
Mastey, Vera
Naumann, Ulrike
Reaney, Matthew
Konidaris, Gerasimos
Sasane, Medha
Brady, Keri J. S.
Li, Siyu
Gullo, Giuseppe
Rietschel, Petra
Sezer, Ahmet
CANCER, 2023, 129 (01) : 118 - 129
[2] Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1
Kilickap, S.
Sezer, A.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Gogishvili, M.
He, X.
Gullo, G.
Rietschel, P.
Quek, R. G.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S125 - S126
[3] EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC with PD-L1 <50%
Rizvi, N.
Lee, S.
Curtis, P.
Caldwell, W.
Gao, B.
Rietschel, P.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S931 - S931
[4] EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%
Rizvi, N.
Lee, S.
Curtis, P.
Caldwell, W.
Gao, B.
Rietschel, P.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S931 - S932
[5] Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
Kilickap, S.
Sezer, A.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Li, S.
Lee, S.
Makharadze, T.
Paydas, S.
Nechaeva, M.
Seebach, F.
Weinreich, D. M.
Yancopoulos, G. D.
Gullo, G.
Lowy, I.
Rietschel, P.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S101 - S101
[6] Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.
Gumus, Mahmut
Chen, Chieh-I
Ivanescu, Cristina
Kilickap, Saadettin
Bondarenko, Igor
Ozguroglu, Mustafa
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Harnett, James
Mastey, Vera
Naumann, Ulrike
Reaney, Matthew
Konidaris, Gerasimos
Sasane, Medha
Brady, Keri
Li, Siyu
Gullo, Giuseppe
Rietschel, Petra
Sezer, Ahmet
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[7] Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1
Gumus, M.
Kilickap, S.
Sezer, A.
Bondarenko, I.
Ozguroglu, M.
Gogishvili, M.
He, X.
Gullo, G.
Rietschel, P.
Quek, R. G.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S321 - S321
[8] "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study"(vol 129, pg 118, 2023)
Gumus, M.
Chen, C-, I
Ivanescu, C.
CANCER, 2024, 130 (09) : 1715 - 1715
[9] Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
Bondarenko, I.
Sezer, A.
Kilickap, S.
Gumus, M.
Ozguroglu, M.
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Mcginniss, J.
Pouliot, J.
Lee, S.
Seebach, F.
Lowy, I.
Gullo, G.
Rietschel, P.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S951 - S951
[10] Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.
Ozguroglu, Mustafa
Sezer, Ahmet
Kilickap, Saadettin
Gumus, Mahmut
Bondarenko, Igor
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Bentsion, Dmitry
Gladkov, Oleg
Clingan, Philip R.
Sriuranpong, Virote
Rizvi, Naiyer A.
McGinniss, Jennifer
Pouliot, Jean-Francois
Lee, Sue
Seebach, Frank A.
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →